目的 探究雷贝拉唑对不同C-X-C趋化因子配体16（CXCL16）表达水平的HP阳性慢性萎缩性胃炎患者治疗效果的观察。方法 回顾性分析贵黔国际医院2022年1月至2023年12月收治105例HP阳性慢性萎缩性胃炎患者为研究对象,按不同CXCL16表达水平分为高表达组（≥2.45 μg/L）70例,低表达组（<2.45 μg/L）35例,给予雷贝拉唑治疗,对比CXCL16表达水平与胃黏膜病理状态及临床疗效等。结果 ROC曲线显示CXCL16对HP阳性慢性萎缩性胃炎预测价值良好;治疗后高表达组PGⅠ/PGⅡ、PGⅠ水平低于低表达组,炎症因子、CK-MB、胃黏膜病理状态评分、GAS、PGⅡ、血钾、TBIL、AST、ALT、ALB水平高于低表达组（P<0.05）;Spearman相关性分析,高、低CXCL16表达水平与治疗效果呈负相关性。结论 雷贝拉唑对不同CXCL16表达水平的HP阳性慢性萎缩性胃炎患者治疗效果显著,改善患者CXCL16水平,提高机体免疫力。
Abstract
Objective To investigate the therapeutic effect of rabeprazole in patients with HP-positive chronic atrophic gastritis with different C-X-C chemokine ligand 16 (CXCL16) expression levels. Methods A retrospective analysis of 105 patients with HP-positive chronic atrophic gastritis admitted to Guijian International Hospital from January 2022 to December 2023 was selected as the study objects. According to different CXCL16 expression levels, 70 cases were divided into a high expression group (≥2.45 μg/L) and 35 cases were divided into a low expression group (<2.45 μg/L). Rabeprazole was given treatment. The expression level of CXCL16 was compared with the pathological status and clinical efficacy of gastric mucosa. Results The ROC curve showed that CXCL16 had good predictive value for HP-positive chronic atrophic gastritis; the levels of PGⅠ/PGⅡ and PGⅠ in the high expression group were lower than those in the low-expression group, and the levels of inflammatory factors, CK-MB, gastric mucosal pathological state score, GAS, PGⅡ, blood potassium, TBIL, AST, ALT, and ALB were higher than those in the low-expression group after the treatment (P < 0.05); Spearman's correlation analysis showed that the high and low CXCL16 expression levels were negatively correlated with the treatment effect. Conclusions The therapeutic effect of rabeprazole on patients with HP-positive chronic atrophic gastritis with different CXCL16 expression levels was significant, improving the patients' CXCL16 levels and enhancing the body's immunity.
关键词
雷贝拉唑 /
C-X-C趋化因子配体16 /
幽门螺杆菌阳性 /
慢性萎缩性胃炎
Key words
Rabeprazole /
C-X-C chemokine ligand 16 /
Helicobacter pylori positivity /
Chronic atrophic gastritis
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 顾丹阳,宫跃敏. 老年慢性萎缩性胃炎患者Hp感染、血清G-17、PG表达水平变化[J]. 湖南师范大学学报(医学版),2021,18(6):124-127.
[2] 程燕红,蒋宝玲. 雷贝拉唑联合吗丁啉治疗慢性萎缩性胃炎的疗效[J]. 贵州医药,2023,47(2):238-239.
[3] Ma S,Li Y,Guo R,et al.The Efficacy of Morodan in Combination with Rabeprazole for the Treatment of Chronic Gastritis and its Impact on Gastric Mucosal Repair[J]. Altern Ther Health Med,2023,29(6):306-310.
[4] 张茗,郭翃江,严之红,等. 缺血性脑卒中后认知功能障碍老年患者血清神经丝轻链蛋白和CXC型趋化因子配体16水平变化及意义[J]. 中华实用诊断与治疗杂志,2022,36(5):500-504.
[5] 中国中西医结合学会消化系统疾病专业委员会. 慢性萎缩性胃炎中西医结合诊疗共识意见(2017年)[J]. 中国中西医结合消化杂志,2018,26(2):121-131.
[6] 中华医学会消化病学分会. 中国慢性胃炎共识意见(2017年,上海)[J]. 中华消化杂志,2017,37(11):721-738.
[7] 张冬雪,石岩岩,丁士刚. 幽门螺杆菌感染致机体应激反应在胃黏膜疾病中的作用[J]. 胃肠病学,2021,26(8):503-506.
[8] Bai WJ,Liang JW,Miao XM,et al.Clinical effects of acupoint catgut embedding with quadruple therapy on Hp (+) chronic atro-phic gastritis of spleen and stomach deficiency syndrome[J]. Zhen Ci Yan Jiu,2022,47(6):537-543.
[9] Liu W,Tian J,Hui W,et al.A retrospective study assessing the acceleration effect of type I Helicobacter pylori infection on the progress of atrophic gastritis[J]. Sci Rep,2021,11(1):4143.
[10] 刘小娟,陈策,张艳芳,等. 雷贝拉唑联合气滞胃痛颗粒治疗慢性萎缩性胃炎患者的临床观察[J]. 中国临床医生杂志,2020,48(2):156-159.
[11] 赵涵,丁娜,商振宁. 慢性萎缩性胃炎规范化治疗效果分析[J]. 中国标准化,2024(12):257-260.
[12] 张鹏飞,杨小飞,许怀利,等. 慢性萎缩性胃炎患者血清ADAM17和CXCL16表达水平与临床价值研究[J]. 现代检验医学杂志,2024,39(1):73-77.
[13] Liu G,Abas O,Strickland AB,et al.CXCR6+CD4+ T cells promote mortality during Trypanosoma brucei infection[J]. PLoS Pathog,2021,17(10):1009968.
[14] 唐欢,陈扬,郑学颖. 雷贝拉唑联合微生态制剂治疗老年功能性消化不良的临床疗效及对患者血清GHR、AchE水平的影响[J]. 中国老年学杂志,2022,42(19):4684-4687.
PDF(671 KB)
